Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Sarcoma 1Pancreatectomy 1Lymphoma, Follicular 1Lung Neoplasms 1Frailty 1Coma 1Colonic Neoplasms 1Cerebrovascular Disorders 1Breast Neoplasms 1Brain Injuries, Traumatic 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × Enhanced Recovery After Surgery × Clear all
NCT04451473 2022-11-16

Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery

The Second Hospital of Shandong University

Phase NA Recruiting
350 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡